BioAge Labs Inc. Common Stock (BIOA)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable moats, honest earnings, and a margin of safety. BioAge is a clinical-stage biopharmaceutical company with only 60 employees. Its lead candidate, BGE-102, is an oral NLRP3 inhibitor in Phase 1 for atherosclerotic cardiovascular disease, and its platform uses human datasets on aging. At this stage the moat is unproven; value depends on trial outcomes, not current cash flows. The filed figures show revenue is small and losses are large. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $2.5M and net loss was $26.1M. In fiscal Q1 2026, revenue was $2.8M and net loss was $22.3M. For FY2025, the period ended 2025-12-31, revenue was $9.0M and net loss was $80.6M. FY2024 and FY2023 had no reported revenue in the filed figures, with net losses of $71.1M and $63.9M. The trailing-twelve-month free cash flow is -$88.1M, a -34.5% FCF yield as FairStock calculates, so cash burn is substantial. At the 2026-10-13 close of $5.57, FairStock calculations show P/B 0.68 and P/E -2.33. ROE is -28.21%, ROCE is -18.47%, Piotroski F-Score is 2/9, and Altman Z-Score is 6.32. Debt-to-equity is 0.01, so leverage is low, but weak returns and a FairStock Score of 26/100 confirm the business is not yet sound. The Lynch category is none because the company lost money in each of the last three years. Without profits, any valuation is speculative. I would need clinical progress and a credible funding path before calling this a bargain.

In plain English: BioAge Labs is a small clinical-stage drug company developing treatments for metabolic diseases tied to aging. It has some revenue but loses money every quarter and burns cash, so the business looks financially weak. The share price is below its accounting value, but with no profits and heavy losses, it is not clearly cheap; it looks speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer